In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3

Neuropsychopharmacology

Volumn 29, Issue 1, 2004, Pages 32-38

  Gould, Todd D ^a   Chen, Guang ^a   Manji, Husseini K ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Laboratory of Molecular Pharmacology   (United States)

Author keywords

Depression; GSK 3; Mania; Manic depressive illness; Valproic acid; Wnt pathway

Indexed keywords

BETA CATENIN; CARBAMAZEPINE; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CARBONATE; MESSENGER RNA; VALPROIC ACID;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INHIBITION; ENZYME REGULATION; FRONTAL CORTEX; MALE; NONHUMAN; POLYURIA; PRIORITY JOURNAL; PROTEIN STABILITY; RAT; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; BETA CATENIN; BLOTTING, WESTERN; BRAIN; CARBAMAZEPINE; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CARBONATE; MALE; RATS; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANS-ACTIVATORS; VALPROIC ACID;

EID: 0346688565     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300283     Document Type: Article

References (54)

1. 2+ in neuroblastoma SH-SY5Y cells: a fluorescence and 31P NMR study. Biophys J 76: 2934-2942.
2. Amari L, Layden B, Rong Q, Geraldes CF, Mota de Freitas D (1999b). Comparison of fluorescence, (31)P NMR, and (7)Li NMR spectroscopic methods for investigating Li(+)/Mg(2+) competition for biomolecules. Anal Biochem 272: 1-7.
3. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW et al (2000). Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA 97: 11074-11079.
4. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. 2+ in cultured cortical neurons. Neuron 11: 751-757.
6. Bustin SA (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25: 169-193.
7. Chalecka-Franaszek E, Chuang DM (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96: 8745-8750.
8. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW et al (2001). Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 152: 87-96.
9. Chenn A, Walsh CA (2002). Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297: 365-369.
10. Cohen P, Frame S (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776.
11. Davies SP, Reddy H, Caivano M, Cohen P (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
12. De Sarno P, Li X, Jope RS (2002). Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164.
13. Ding VW, Chen RH, McCormick F (2000). Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 275: 32475-32481.
14. Doble BW, Woodgett JR (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.
15. Dorronsoro I, Castro A, Martinez A (2002). Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs. Expert Opin Ther Patents 12: 1527-1536.
16. Eldar-Finkelman H (2002). Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8: 126-132.
17. Elyaman W, Terro F, Wong NS, Hugon J (2002). In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: links to tau phosphorylation. Eur J Neurosci 15: 651-660.
18. Frame S, Cohen P (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16.
19. Gee II JB, Corbett RJ, Perlman JM, Laptook AR (2001). Hypermagnesemia does not increase brain intracellular magnesium in newborn swine. Pediatr Neurol 25: 304-308.
20. 2+ increase during depolarization in cultured neurons. Brain Res 828: 163-168.
21. Gould TD, Chen G, Manji HK (2002). Mood stabilizer psychopharmacology. Clin Neurosci Res 2: 193-212.
22. Gould TD, Manji HK (2002). The wnt signaling pathway in bipolar disorder. Neuroscientist 8: 497-511.
23. Grimes CA, Jope RS (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426.
24. Gurvich N, Klein PS (2002). Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 96: 45-66.
25. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM et al (1995). The molecular basis of Turcot's syndrome. N Engl J Med 332: 839-847.
26. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P et al (2000). APC mutations in sporadic medulloblastomas. Am J Pathol 156: 433-437.
27. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459.
28. Koch A, Waha A, Tonn JC, Sorensen N, Berthold F, Wolter M et al (2001). Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93: 445-449.
29. Lee CW, Lau KF, Miller CC, Shaw PC (2003). Glycogen synthase kinase-3beta-mediated tau phosphorylation in cultured cell lines. Neuroreport 14: 257-260.
30. Lee Y, Hamamura T, Ohashi K, Miki M, Fujiwara Y, Kuroda S (2000). Carbamazepine suppresses methamphetamine-induced Fos expression in a regionally specific manner in the rat brain. Possible neural substrates responsible for antimanic effects of mood stabilizers. Neuropsychopharmacology 22: 530-537.
31. Li-Smerin Y, Levitan ES, Johnson JW (2001). Free intracellular Mg(2+) concentration and inhibition of NMDA responses in cultured rat neurons. J Physiol 533: 729-743.
32. Marangos PJ, Weiss SR, Montgomery P, Patel J, Narang PK, Cappabianca AM et al (1985). Chronic carbamazepine treatment increases brain adenosine receptors. Epilepsia 26: 493-498.
33. Martinez A, Castro A, Dorronsoro I, Alonso M (2002). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 22: 373-384.
34. Masuda CA, Xavier MA, Mattos KA, Galina A, Montero-Lomeli M (2001). Phosphoglucomutase is an in vivo lithium target in yeast. J Biol Chem 10: 10.
35. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J (1997). Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 411: 183-188.
36. Peifer M, Polakis P (2000). Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 287: 1606-1609.
37. Phiel CJ, Klein PS (2001). Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789-813.
38. Planel E, Yasutake K, Fujita SC, Ishiguro K (2001). Inhibition of protein phosphatase 2A overrides Tau protein kinase I/glycogen synthase kinase 3b and cyclin-dependant kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 5: 5.
39. Ray Jr WJ, Szymanki ES, Ng L (1978). The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim Biophys Acta 522: 434-442.
40. Rhyu GI, Ray Jr WJ, Markley JL (1984). Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase. Phosphorus NMR studies. Biochemistry 23: 252-260.
41. Ryves WJ, Harwood AJ (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280: 720-725.
42. Shaldubina A, Agam G, Belmaker RH (2001). The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry 25: 855-866.
43. Sharpe C, Lawrence N, Martinez Arias A (2001). Wnt signalling: a theme with nuclear variations. BioEssays 23: 311-318.
44. Spittaels K, Van den Haute C, Van Dorpe J, Terwel D, Vandezande K, Lasrado R et al (2002). Neonatal neuronal overexpression of glycogen synthase kinase-3beta reduces brain size in transgenic mice. Neuroscience 113: 797.
45. Stambolic V, Ruel L, Woodgett JR (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664-1668.
46. Suzui M, Ushijima T, Dashwood RH, Yoshimi N, Sugimura T, Mori H et al (1999). Frequent mutations of the rat beta-catenin gene in colon cancers induced by methylazoxymethanol acetate plus 1-hydroxyanthraquinone. Mol Carcinogen 24: 232-237.
47. Weiss SR, Nguyen T, Rubinow DR, Heike CJ, Narang PK, Post RM et al (1987). Lack of effect of chronic carbamazepine on brain somatostatin in the rat. J Neural Transm 68: 325-333.
48. Weiss SR, Post RM (1987). Carbamazepine and carbamazepine-10,11-epoxide inhibit amygdala-kindled seizures in the rat but do not block their development. Clin Neuropharmacol 10: 272-279.
49. Wodarz A, Nusse R (1998). Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14: 59-88.
50. Woodgett JR (2001). Judging a protein by more than its name: gsk-3. Sci STKE 2001: RE12.
51. York JD, Ponder JW, Majerus PW (1995). Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci USA 92: 5149-5153.
52. Yuan H, Mao J, Li L, Wu D (1999a). Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation. J Biol Chem 274: 30419-30423.
53. Yuan P, Chen G, Manji HK (1999b). Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo. J Neurochem 73: 2299-2309.
54. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001). The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276: 31674-31683.